PCOS is Now Called PMOS — What This Name Change Means for Women

Q: Why was PCOS renamed to PMOS?

The name was changed because PCOS was misleading — the 'cystic' label implied ovarian cysts, which are not actually cysts but follicles. The new name PMOS (Polyendocrine Metabolic Ovarian Syndrome) better reflects the hormonal and metabolic nature of the condition.

If you have been living with a PCOS diagnosis, you may have recently seen news about a major name change in the medical world. In May 2026, The Endocrine Society — joined by more than 50 global health organisations — announced that Polycystic Ovary Syndrome (PCOS) will be officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This is not a minor administrative update. After 14 years of international scientific collaboration, experts determined that the old name was fundamentally misleading and was causing real harm to women's health outcomes.

At Mother Hospitals & IVF Center in Hyderabad, Dr. E. Prashanthi Reddy has been managing PCOS/PMOS for over 19 years. Here, we explain what this name change means, why it happened, and — most importantly — what it means for women living with this condition, including those trying to conceive.

Why Was the Name Changed in the First Place?

The name "Polycystic Ovary Syndrome" has been in use since the 1930s, when early ultrasound technology showed what appeared to be multiple cysts on the ovaries of affected women. However, these are not actually cysts in the medical sense. They are immature follicles — small fluid-filled sacs that contain developing eggs. In healthy cycles, one follicle matures and releases an egg. In PMOS, multiple follicles start to develop but none reaches full maturity, leading to irregular or absent ovulation.

The "cystic" label has misled both patients and some clinicians for decades. Many women with the condition were told they had ovarian cysts and underwent unnecessary surgeries. Others were not adequately treated for the broader metabolic aspects of the condition because the name drew attention exclusively to the ovaries.

Key fact: Approximately 1 in 8 women worldwide — around 170 million people — are affected by this condition. It is one of the most common hormonal disorders of reproductive age, yet for decades its name described a symptom (follicles mistaken for cysts) rather than the underlying disease mechanism.

What Does PMOS Actually Mean?

The new name — Polyendocrine Metabolic Ovarian Syndrome — is far more descriptive of what is actually happening in the body:

Polyendocrine: Multiple hormonal systems are affected, not just the ovaries. These include insulin, cortisol, thyroid hormones, and androgens (male hormones such as testosterone).
Metabolic: The condition is fundamentally a metabolic disorder, involving insulin resistance, abnormal glucose metabolism, and increased risk of type 2 diabetes and cardiovascular disease.
Ovarian: The ovaries are still involved — the disrupted hormonal environment leads to anovulation (lack of ovulation) and the characteristic appearance on ultrasound.
Syndrome: It remains a syndrome because it is diagnosed based on a cluster of symptoms rather than a single definitive test.

What Is the Timeline for This Change?

The announcement in May 2026 marks the beginning of a 3-year transition period. Full implementation of the PMOS terminology across medical institutions, health records, insurance coding systems, and patient education materials is expected by 2028. During this period, both PCOS and PMOS will be used, and patients should not be alarmed if they continue to see PCOS in their records or prescriptions.

India's medical community is expected to align with international standards progressively. Hospitals affiliated with FOGSI (Federation of Obstetric and Gynaecological Societies of India) and other national bodies will issue their own guidance as the global transition proceeds.

Does This Change Your Treatment?

The name change does not immediately alter standard treatment protocols. However, it is expected to have meaningful long-term consequences for how women with PMOS are managed:

Greater Focus on Metabolic Health

Under the old PCOS framework, many doctors focused primarily on regulating periods and managing fertility. The PMOS name signals to all clinicians that the metabolic components — insulin resistance, blood sugar, cholesterol, and cardiovascular risk — must be assessed and treated with equal seriousness, even in young women.

Earlier Screening for Comorbidities

Women with PMOS will now be more systematically screened for type 2 diabetes, non-alcoholic fatty liver disease, obstructive sleep apnoea, and depression — conditions that are significantly more common in this population but were often overlooked when the disorder was viewed primarily as a gynaecological issue.

Improved Diagnostic Criteria

International working groups are also revisiting the Rotterdam Criteria (the current diagnostic standard), which requires two of three findings: irregular cycles, elevated androgens, or polycystic-appearing ovaries. Future criteria may place greater weight on metabolic markers, leading to better identification of women who do not fit the classic presentation.

Dr. Prashanthi's perspective: "At Mother Hospitals, we have always taken a whole-body approach to PCOS — checking insulin resistance, thyroid function, and metabolic markers alongside ovarian assessment. The PMOS renaming validates this integrative approach and will encourage more clinicians to do the same. For our patients, nothing changes about the quality of care they receive — but this shift will improve standards nationally."

What It Means for Women Trying to Conceive

PMOS remains one of the most common causes of anovulatory infertility — meaning infertility caused by the absence of regular ovulation. The fertility management pathway does not change with the rename, but the broader metabolic context becomes even more important:

Treating insulin resistance with lifestyle changes or metformin continues to be foundational — it can restore ovulation in a significant proportion of women without any fertility medication.
For women requiring assisted reproduction, individualised IVF protocols are essential. Women with PMOS are at higher risk of ovarian hyperstimulation syndrome (OHSS) and need careful dose titration.
Weight management, while not a prerequisite for treatment, significantly improves outcomes — even a 5–10% reduction in body weight can restore ovulation in overweight women with PMOS.
Comprehensive hormonal profiling — including thyroid, prolactin, insulin, and androgen levels — should precede any fertility treatment.

Emotional Impact of the Rename

For many women, the word "cystic" in PCOS created anxiety about their ovaries being damaged or diseased. The new name PMOS removes this misleading connotation. Advocacy groups have long argued that the old name contributed to stigma, confusion, and delayed diagnosis. Women who were told "you have cysts on your ovaries" sometimes avoided treatment out of fear or misunderstanding.

The PMOS name shift also opens the door to greater awareness. Because it names the metabolic and endocrine dimensions, it may help more women recognise symptoms such as fatigue, brain fog, weight gain, and skin changes as connected to the same condition that causes irregular cycles — symptoms that were frequently dismissed or attributed to other causes.

What Should You Do Right Now?

If you have a PCOS diagnosis, no action is immediately required. Your diagnosis remains valid. However, this is a good time to:

Ask your doctor for a comprehensive metabolic workup if you have not had one recently (fasting insulin, HbA1c, lipid profile, thyroid function)
Discuss whether your current treatment plan addresses both the ovarian and metabolic aspects of your condition
If you are trying to conceive, consult a fertility specialist who understands the full PMOS picture — not just ovulation induction
Stay updated through reliable sources such as endocrine.org, where the official announcement and transition documents are published

Have Questions? Talk to Dr. Prashanthi

Get a personalised fertility assessment at Mother Hospitals & IVF Center, Boduppal

📞 97059 93366 💬 WhatsApp

Frequently Asked Questions

Why was PCOS renamed to PMOS?

The name was changed because PCOS was misleading — the "cystic" label implied ovarian cysts, which are not actually cysts but follicles. The new name PMOS (Polyendocrine Metabolic Ovarian Syndrome) better reflects the hormonal and metabolic nature of the condition, encouraging more complete treatment.

When did the PCOS to PMOS name change happen?

The Endocrine Society along with 50+ global organisations announced the rename in May 2026 after 14 years of international collaboration. A 3-year transition period is underway, with full implementation expected by 2028. Both terms will be used during this period.

Does the name change affect my treatment?

The name change itself does not alter your existing treatment immediately. However, PMOS framing encourages doctors to give more weight to the metabolic aspects — insulin resistance, thyroid function, and cardiovascular risk — alongside managing cycles and fertility, leading to more comprehensive care over time.

Will my medical records and prescriptions change immediately?

Not immediately. The 3-year transition period allows clinicians, hospitals, and health systems to update their records, coding, and patient education materials progressively. Both PCOS and PMOS will be used simultaneously during this period.

Can women with PMOS (formerly PCOS) get pregnant with IVF?

Yes. Women with PMOS can absolutely conceive with proper treatment. Depending on individual factors, treatment may range from lifestyle changes and ovulation induction to IUI or IVF. At Mother Hospitals, Dr. Prashanthi tailors protocols specifically for women with PMOS to optimise outcomes while minimising OHSS risk.